CompletedNCT00126009
Valproate with amisulpride or haloperidol for mania in bipolarity
About this title
Read the official source — NCT00126009This study evaluated the safety and effectiveness of Amisulpride for people with bipolarity.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Amisulpride for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Prague and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France, Czechia, Poland, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00126009
- Official title
Show the full official title
A 3-Month, Open, Randomised Trial Comparing the Efficacy and Safety of the Association Valproate-Amisulpride to the Association Valproate-Haloperidol in Bipolar I Patients Suffering From a Manic Episode
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedPrague, Czechia · Paris, France · Warsaw, Poland
3 more locations
- Bratislava, Slovakia
- Barcelona, Spain
- Czechia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Amisulpride for people with bipolarity.
Who is behind this study?
The study sponsor is Sanofi.
Did this study involve medication?
Yes. The study involved medication, including Amisulpride.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...